Skip Navigation LinksHome > Current Issue > Fertility preservation and reproductive health in the pediat...
Current Opinion in Obstetrics & Gynecology:
doi: 10.1097/GCO.0000000000000107
ADOLESCENT AND PEDIATRIC GYNECOLOGY: Edited by Paula J. Adams Hillard

Fertility preservation and reproductive health in the pediatric, adolescent, and young adult female cancer patient

Trudgen, Kourtneya; Ayensu-Coker, Leslieb

Collapse Box

Abstract

Purpose of review

As treatments for malignancies become increasingly successful, emphasis on quality of life in survivorship becomes important. Of equal importance is the role of gonadotoxic agents in the management of chronic medical conditions, such as nonmalignant blood disorders and rheumatologic and genetic conditions. Gonadotoxic agents have long-term effects to include ovarian insufficiency, pubertal arrest and subsequent infertility.

Recent findings

In 2004, ovarian tissue cryopreservation emerged as an investigational but viable option for prepubertal patients and those unable to undergo ovarian stimulation. In 2012, oocyte preservation became standard therapy for patients without a partner or who elected not to use donor sperm or freeze embryos. Ovarian reserve testing with antimullerian hormone to assess fertility after gonadotoxic therapy is a rapidly growing area of interest with potentially significant benefits in personalizing the approach to fertility preservation.

Summary

A systematic approach to fertility preservation prior to treatment in all patients receiving gonadotoxic agents optimizes care. Fertility preservation strategies can restore hormonal function and preserve reproductive potential. Future research in personalizing approach to care is critical to meeting the needs of this patient population.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.